Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Enspryng ™(satralizumab-mwge)…
Press
The U.S. Food and Drug Administration today approved Uplizna (inebilizumab-cdon) injection for intravenous use for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult…
Alexion Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved SOLIRIS® (eculizumab) for the treatment of neuromyelitis optica spectrum disorder (NMOSD)…
WALTHAM, Mass. and BEVERLY HILLS, Calif., March 30, 2021 /PRNewswire/ — CorEvitas and The Guthy-Jackson Charitable Foundation (GJCF) are excited to announce plans for launching the SPHERES (Synergy of Prospective Health & Experimental Research…
Learn about the four main advocacy groups in NMOSD, and their incredible origin stories. Click here to view the full article.
Satralizumab represents a potential new approach to treating neuromyelitis optica spectrum disorder (NMOSD), a rare, debilitating disease often misdiagnosed as multiple sclerosis (MS)… Click here…
Featured Videos
